As other CROs strive to become the biggest providers of research services, MPI Research is working to expand our position as the best, and most responsive, preclinical service provider. MPI Research created the department of Experimental Therapeutics three years ago in response to sponsor requests for help with in vivo proof of concept and efficacy studies. The group continues to grow, driven by partnerships with clients to develop models to meet their specific needs. The new models developed recently support multiple therapeutic areas including; oncology, infectious disease, gastrointestinal, cardiovascular and cell based therapies.

2004 has seen a diverse variety of models developed, such as:

Oncology
• Xenograft pancreatic tumor models in nude mice
• Stereotactic implanted brain tumors in rats
• Chemotherapy induced anemia model in mice

Anti-infectives
• LD50 and ED50 bacteremia models in mice utilizing several strains of staphylococcus
• Chinchilla otitis media model (Haemophilus and Pneumococcus sp.) under development

Cardiovascular and gastrointestinal drug efficacy
• Atherosclerotic models in Watanabe rabbits
• DSS induced colitis in mice

Kate Lane Ph.D., Director of Experimental Therapeutics for MPI Research commented, “MPI Research developed the xenograft tumor models in response to a single sponsor’s request. From this single model grew the current Experimental Therapeutics Department. The new models added this year are a testament to our desire to aid our sponsors’ efforts in developing new therapies to treat a wide variety of diseases. If models do not exist to meet current needs, we are able and willing to partner with our customers to develop appropriate models. We are extremely privileged to have assembled such a diverse and talented team, allowing us to address a broad range of needs for our sponsors.”

MPI Research exists to provide comprehensive preclinical research that meets the requirements of pharmaceutical, medical device, animal health and chemical companies as well as governmental agencies as we partner together to bring safer, healthier products to the world. MPI Research employees specialize in a wide variety of scientific disciplines including toxicology, pharmacology, metabolism, pathology, clinical pathology, reproductive and developmental biology, veterinary science, neuroscience, experimental therapeutics, immunotoxicology, analytical chemistry, computer science, regulatory science, and statistics.

Home | News